There are no upcoming webinars at this time, please check back soon.
Detecting the Undetectable: Development & Validation of Ultrasensitive Simoa-based Immunoassay Services
Reliably detecting immuno-modulating proteins in serum and plasma from normal individuals has historically been impossible due to the lack of sensitivity of conventional immunoassays. Quanterix and Myriad RBM are working together to change this paradigm via ultrasensitive, high quality immunoassay services that offer drug developers an unparalleled approach to clinical research.
Detecting the Undetectable: Development and Validation of Ultrasensitive Simoa-based Assays to Reproducibly Measure Immune System Regulatory Proteins in Human Blood Samples
Quanterix’s ultrasensitive single molecule array (Simoa) technology enables the accurate measurement of protein biomarkers that were previously difficult or even impossible to detect in blood samples.
Vectra® DA: A Multi-Biomarker Blood Test for Assessing Disease Activity in Patients with Rheumatoid Arthritis
This presentation will summarize: the development and validation of Vectra DA, the basis for its clinical utility, and how Vectra DA can be helpful to clinical trials of pharmaceutical agents.
Detection of Subclinical Interstitial Lung Disease: A Potential Role for Targeted Blood Biomarker Profiling
The general purpose of our translational research studies is to identify clinical tools for the detection of subclinical parenchymal lung disease.
Standardized Assays for Personalized Immune Response Monitoring
This online seminar provides an overview of research published in Immunity that demonstrates progress in the standardization of assays for personalized immune response monitoring.